由METTL14介导的m6A修饰上调的SOCS3表达通过调节JAK2/STAT3通路来缓解甲状腺癌的进展
Ming Zhou1, Yaqi Zhang2, Qiong Zhang3
1Department of Thyroid Vascular Surgery, Jingzhou Central Hospital, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, 434000, China.
Molecular and cellular probes
|October 16, 2024
概括
甲基转移酶样14 (METTL14) 在甲状腺癌 (TC) 中降低. 增加METTL14通过调节SOCS3 / JAK2 / STAT3通路来抑制TC进展,提供潜在的治疗点.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 甲状腺癌 (TC) 是最常见的头恶性瘤.
- N6-甲基氨酸 (m6A) 修饰是癌症中的关键表观遗传调节剂.
- 在TC中METTL14介导的m6A的作用尚未完全理解.
研究的目的:
- 研究甲状腺癌进展中的METTL14的功能和机制.
- 在TC中阐明涉及METTL14,m6A,SOCS3和JAK2/STAT3信号通路的调节通路.
主要方法:
- 对TC组织和细胞中METTL14表达的分析.
- 在体外和体内实验中评估METTL14上调对TC细胞的影响.
- 研究涉及m6A修饰,SOCS3表达和JAK2/STAT3通路的分子机制.
- 使用JAK2/STAT3抑制剂 (AG490,WP1066) 来验证该途径.
主要成果:
- 在TC组织和细胞中,METTL14表达显著下降.
- METTL14的上调抑制了TC细胞的增殖,上皮-介质细胞过渡 (EMT) 和瘤生长,同时诱导了亡.
- 通过m6A修饰,METTL14促进了SOCS3的表达,这反过来又使JAK2/STAT3通路失活.
- 抑制SOCS3或激活JAK2/STAT3通路可以逆转METTL14的抑制作用.
结论:
- 在甲状腺癌中,METTL14充当瘤抑制剂.
- METTL14/m6A/SOCS3/JAK2/STAT3轴是TC进展的一个关键调节器.
- METTL14代表了甲状腺癌治疗的潜在治疗标.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K


